Gapping up
In reaction to strong earnings/guidance:
- GPK +13.9%, EFX +7.2%, STLD +5.2%, SJM +1.7% (raises FY20 EPS and revenue guidance), CCK +1.5%, EMR +1.2%
Other news:
- APDN +27.3% (Applied DNA Sciences signs agreement with Stony Brook University Hospital for Applied DNA High-Sensitivity and High-Throughput COVID-19 diagnostic kit)
- CARA +20.4% (Cara Therapeutics and VFMCRP report positive results from global KALM-2 pivotal phase-III trial of KORSUVA)
- LH +4.5% (receives Emergency Use Authorization from FDA for COVID-19 at-home test kit)
- CWEN +4.3% (to acquire and invest in a portfolio of renewable energy projects)
- SGMO +3.2% (Sangamo Therapeutics and Mogrify announce collaboration and license agreement for iPSC- and ESC-derived regulatory T cells)
- CERS +2% (announces expansion of BARDA contract)
- CHH +0.8% (announces workforce reductions)
Analyst comments:
- TX +1.7% (upgraded to Buy from Neutral at Citigroup)
- TFC +1.1% (upgraded to Overweight from Neutral at Piper Sandler)